lobbying_activities: 3144180

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3144180	cdfab3a0-b4ff-4914-be3b-787af7e47f61	Q1	FORBES-TATE	400976792	AMGEN USA, INC.	2024	first_quarter	MED	Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.	HOUSE OF REPRESENTATIVES,SENATE	80000		0	0	2024-04-14T21:03:02-04:00